Abstract
<jats:p>Hepatitis C virus (HCV) infection remains a major global health challenge despite the success of direct-acting antivirals (DAAs), which are limited by high cost, restricted accessibility, and the emergence of resistant strains. Natural products, particularly phytochemicals, represent a promising reservoir of antiviral agents with diverse mechanisms of action and favorable safety profiles. In this study, we combined wet-lab experimentation with computational approaches to identify plant-derived molecules capable of inhibiting HCV entry. Guided by ethnobotanical evidence, methanolic leaf extracts of Psidium guajava L., Plumeria alba L., Syzygium cumini L., and Tamarindus indica L. were prepared and evaluated for cytotoxicity in Huh7 hepatoma cells. Entry inhibition was assessed using EGFP-labelled HCV pseudoparticles (HCVpp) by qRT-PCR and confocal microscopy. Among the tested plants, Tamarindus indica extract significantly reduced KGFP expression (p < 0.05), confirmed by ΔΔCq analysis and impaired membrane fusion events, while Psidium guajava and Plumeria alba impaired intracellular trafficking without blocking initial attachment. Syzygium cumini showed no inhibitory effect under the tested conditions. Complementary in silico analyses included homology modelling, molecular docking, ADME/toxicity profiling, and molecular dynamics simulations of HCV E2?ligand complexes. Literature mining identified 39 candidate compounds, among which lupeol exhibited stable binding interactions with HCV E2 and favorable pharmacokinetic properties. Critically, in vitro binding assays confirmed that lupeol disrupted the E2–CD81 interaction, reducing bound E2-EGFP to 6% compared to controls. This was supported by HCV-pseudoparticle entry assays confirming inhibition of entry. Together, these findings establish Tamarindus indica and lupeol as potent HCV entry inhibitors.</jats:p>